Thank you to our sponsors AG1: Carbon: Function: Timestamps (00:00) Craig Heller (00:26) Deliberate Cold Exposure, Cold Showers, Ice Baths
Retrieved 14 June 2025
Particularly when the treatment is delivered via injections
If other measures prove ineffective, switching to a different GLP-1 medication or discontinuing them altogether may be the best solution

In adults with obesity or overweight with 1 weight-related comorbidity, along with diet and exercise, A well-studied safety profile: Pooled safety data from 3 weight-management clinical trials evaluating Wegovy 2.4 mg pen 1 6.8% of patients treated with Wegovy and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions 1 Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of patients treated with Wegovy vs 0.7% of patients treated with placebo 1 The most common adverse reactions leading to discontinuation were: Nausea (1.8% vs 0.2%) , vomiting (1.2% vs 0%) , and diarrhea (0.7% vs 0.1%) for Wegovy and placebo, respectively 2 *Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort, and epigastric discomfort
Product Specifications & Ingredients Active Ingredient: Semaglutide (5mg)